other

GA-map Dysbiosis Test

2156111

13080 USD

GA-map Dysbiosis Test

The GA-map Dysbiosis Test Lx v2 is a diagnostic test that allows mapping of the intestinal microbiota profile for a selected set of bacteria, and diagnosis of dysbiosis of patients in a clinical setting. The GA-map Dysbiosis Test Lx v2 is based on advances in DNA profiling using probes targeting variable regions (V3 to V7) of the bacterial 16S rRNA gene to characterize and identify bacteria present (Casén C et al. (2015) Aliment Pharmacol Ther.). The targets are identified in a molecular multiplex assay that utilizes the Single Nucleotide Primer Extension (SNuPE) technology patented by professor Knut Rudi (US6617138). A unique algorithm takes advantage of all the data generated by the detection of the SnuPE products to determine dysbiosis level in the sample. The algorithm is incorporated in the GA-map Dysbiosis Analyzer software that accompanies the test.

Gastrointestinal

Human

RUO

13080 USD